Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma

MLA

Emeline, Colomba, et al. “Response to First Line Platinum-Based Chemotherapy in Mismatch Repair Deficient (MMRd)/ Microsatellite Instability High (MSI-High) Endometrial Carcinoma.” Gynecologic Oncology, vol. 169, Feb. 2023, pp. 78–84. EBSCOhost, https://doi.org/10.1016/j.ygyno.2022.11.029.

APA

Emeline, C., Jérôme, A., Gwénaël, L. T., Catherine, G., Dahna, C., Isabelle Ray, C., Pierre Emmanuel, B., Sixtine, de P., Christophe, S., Michel, F., Nicolas, D., Florence, J., Jean Sebastien, F., Patricia, P., & Alexandra, L. (2023). Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. Gynecologic Oncology, 169, 78–84. https://doi.org/10.1016/j.ygyno.2022.11.029

Chicago

Emeline, Colomba, Alexandre Jérôme, Le Teuff Gwénaël, Genestie Catherine, Coupez Dahna, Coquard Isabelle Ray, Brachet Pierre Emmanuel, et al. 2023. “Response to First Line Platinum-Based Chemotherapy in Mismatch Repair Deficient (MMRd)/ Microsatellite Instability High (MSI-High) Endometrial Carcinoma.” Gynecologic Oncology 169 (February): 78–84. doi:10.1016/j.ygyno.2022.11.029.